Efficacy and safety of turoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated Chinese patients with haemophilia A

Registry ID

EUCTR2013-004791-35

Source registry

EUCTR

Phase

PHASE3

Sponsor

Novo Nordisk A/S’

Last update

2026-08-16

Conditions

• Haemophilia A

Summary

To evaluate the clinical efficacy of turoctocog alfa in treatment of bleeding episodes in Chinese patients with severe haemophilia A (FVIII≤1%)

Related clinical trials

• Prevention of bleeding in haemophilia A by prophylactic treatment with Nuwiq®
• A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
• Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®)
• A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
• Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
• Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

View on source registry